«We've known for some time that giving
cyclophosphamide after a transplant helps prevent GVHD, and our study provides an important piece of the puzzle for why it works.»
Not exact matches
In the early 2000s, Johns Hopkins scientists Leo Luznik and Ephraim Fuchs found that giving patients high doses of
cyclophosphamide — a drug derived from nitrogen mustard and used to treat blood cancers — three days
after bone marrow
transplant successfully thwarts acute and chronic GVHD.
Patients receiving standard immunosuppressive drugs
after transplant, as opposed to high - dose
cyclophosphamide, have slower recovery of regulatory T - cells in their blood, adds Kanakry.
After the
transplant, patients receive two days of
cyclophosphamide to prevent GVHD and rejection of the new bone marrow.
Johns Hopkins Kimmel Cancer Center scientists first used
cyclophosphamide to prevent severe graft - versus - host disease (GVHD)
after bone marrow
transplant involving haploidentical or «half - matched»
transplants, a treatment first used in 2000 at the Cancer Center to treat leukemias and other blood cancers.
Patients receive
cyclophosphamide for two days
after their bone marrow
transplant, in addition to two other chemotherapy drugs given before the
transplant.